Table 2 Multivariate analysis for cancer-specific survival
Variable | 5 year survival rate(%) | Univariate p Value | Multivariate HR (95% CI) | Multivariate p Value |
|---|---|---|---|---|
Age (< 75 / ≥75) | 85.4 / 76.4 | 0.31 | ||
Sex (M/F) | 83.4 / 81.6 | 0.72 | ||
Tumor number (single / multi) | 89.0 / 59.0 | < 0.01 | 4.30 (1.50–14.1) | < 0.01 |
Tumor size (< 2/≥2 cm) | 93.2 / 80.1 | 0.08 | 2.76 (0.58–20.7) | 0.21 |
ICG R15 (< 15/≥15 cm) | 83.8 / 80.3 | 0.57 | ||
Differentiation (well-mod / por) | 84.3 / 69.0 | 0.13 | ||
Stage (I,II / III, IV) | 90.8 / 68.0 | < 0.01 | 1.35 (0.31–6.32) | 0.68 |
AFP (< 10/≥10 ng/ml) | 92.8 / 73.8 | < 0.01 | 3.51 (1.25–11.9) | 0.01 |
PIVKA-II (< 400/≥400 AU/ml) | 90.5 / 66.9 | < 0.01 | 1.84 (0.74–4.78) | 0.18 |
vp ( - / +) | 86.6 / 67.1 | < 0.01 | 1.24 (0.40–3.99) | 0.7 |
vv ( - / +) | 84.5 / 48.6 | 0.07 | 3.84 (0.76–15.1) | 0.09 |
Myosteatosis (- / +) | 88.4 / 71.7 | 0.03 | 2.47 (1.04–6.10) | 0.03 |